Susana Rives

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5104421/publications.pdf

Version: 2024-02-01

84	5,332	304368	88477
papers	citations	22 h-index	70 g-index

91	91	91	7739
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood, 2022, 139, 1785-1793.	0.6	28
2	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. Blood Cancer Discovery, 2022, 3, 66-81.	2.6	70
3	Native E. coli asparaginase upfront should be replaced by PEGasparaginase upfront in the treatment of pediatric patients with acute lymphoblastic leukemia. Hematological Oncology, 2022, 40, 809-811.	0.8	0
4	Results of <scp>ARI</scp>â€0001 <scp>CART19</scp> cell therapy in patients with relapsed/refractory <scp>CD19</scp>â€positive acute lymphoblastic leukemia with isolated extramedullary disease. American Journal of Hematology, 2022, 97, 731-739.	2.0	6
5	Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LALâ€SEHOPâ€PETHEMAâ€2013. Journal of Thrombosis and Haemostasis, 2022, 20, 1390-1399.	1.9	7
6	Technical Validation and Clinical Utility of an NGS Targeted Panel to Improve Molecular Characterization of Pediatric Acute Leukemia. Frontiers in Molecular Biosciences, 2022, 9, 854098.	1.6	4
7	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia, 2022, 36, 1508-1515.	3.3	21
8	CD34+CD19â^'CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood, 2022, 140, 38-44.	0.6	20
9	Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia, 2022, 36, 1516-1524.	3.3	21
10	Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia. Bone Marrow Transplantation, 2021, 56, 376-386.	1.3	11
11	CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. Molecular Therapy, 2021, 29, 636-644.	3.7	80
12	Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Advances, 2021, 5, 593-601.	2.5	28
13	Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia. Clinical and Translational Oncology, 2021, 23, 1963-1966.	1.2	3
14	The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clinical and Translational Oncology, 2021, 23, 2489-2496.	1.2	3
15	Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Advances, 2021, 5, 2901-2908.	2.5	29
16	Lower incidence of clinical allergy with PEGâ€asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEGâ€ASP in pediatric patients with acute lymphoblastic leukemia. Hematological Oncology, 2021, 39, 687-696.	0.8	5
17	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
18	Outcomes for paediatric acute leukaemia patients admitted to the paediatric intensive care unit. European Journal of Pediatrics, 2021, 181, 1037.	1.3	4

#	Article	IF	Citations
19	Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?. Frontiers in Pediatrics, 2021, 9, 784024.	0.9	13
20	Factors associated with the clinical outcome of patients with relapsed/refractory CD19⁺ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. , 2021, 9, e003644.		11
21	Immunotherapy with CAR-T cells in paediatric haematology-oncology. Anales De PediatrÃa (English) Tj ETQq1 1 0.784314 rgBT /Overlock	0.1	0
22	Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARSâ€CoVâ€2 pandemic. Pediatric Blood and Cancer, 2020, 67, e28557.	0.8	31
23	P09.05â€…Immunogenicity induced by the academic chimeric antigen receptor CAR19 (ARI-0001) in patients with CD19-positive relapsed/refractory B-cell malignancies recruited into the CART19-BE-01 clinical trial. , 2020, 8, A54.1-A54.		0
24	Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia. Journal of Personalized Medicine, 2020, 10, 244.	1.1	1
25	Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. Frontiers in Immunology, 2020, 11, 482.	2.2	77
26	CAR-T immunotherapy in paediatric haemato-oncologyâ€¦ present and future. Anales De PediatrÃa (English Edition), 2020, 93, 1-3.	0.1	0
27	Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. European Journal of Cancer, 2020, 132, 11-16.	1.3	155
28	Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP). British Journal of Haematology, 2020, 190, 764-771.	1.2	20
29	Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment. Frontiers in Pediatrics, 2020, 8, 614521.	0.9	3
30	A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study. Blood, 2020, 136, 8-9.	0.6	10
31	Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).. Journal of Clinical Oncology, 2020, 38, 10518-10518.	0.8	10
32	Impact of polymorphisms in apoptosisâ€related genes on the outcome of childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 185, 159-162.	1.2	1
33	ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain. Clinical and Translational Oncology, 2019, 21, 1763-1770.	1.2	2
34	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 1710-1718.	5.1	65
35	Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial. Biology of Blood and Marrow Transplantation, 2019, 25, S126-S127.	2.0	16
36	PS1214 INFECTIOUS COMPLICATIONS FOLLOWING ARIâ€0001 CELL (A3B1:CD8:4â€“1BB:CD3Z CART19) TREATMENT IN ADULT AND PEDIATRIC PATIENTS WITH CD19+ RELAPSED / REFRACTORY MALIGNANCIES. HemaSphere, 2019, 3, 553-554.	1.2	0

#	Article	IF	Citations
37	PS1455 RESPONSE TO UPâ€FRONT AZACITIDINE IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML): INTERIM ANALYSIS OF THE PROSPECTIVE EUROPEAN MULTICENTER STUDY AZAâ€JMMLâ€001. HemaSphere, 2019, 3, 669.	1.2	0
38	S1618 TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGHâ€RISK CYTOGENETIC ABNORMALITIES. HemaSphere, 2019, 3, 746-747.	1.2	1
39	Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. Molecular Therapy - Methods and Clinical Development, 2019, 12, 134-144.	1.8	77
40	Abstract CT077: Potential utility of minimal residual disease (MRD) to identify relapse in pediatric and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients treated with tisagenlecleucel. , 2019, , .		3
41	Abstract CT077: Potential utility of minimal residual disease (MRD) to identify relapse in pediatric and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients treated with tisagenlecleucel. , 2019, , .		1
42	Upfront azacitidine (AZA) in juvenile myelomonocytic leukemia (JMML): Interim analysis of the prospective AZA-JMML-001 study.. Journal of Clinical Oncology, 2019, 37, 10031-10031.	0.8	7
43	Abstract CT237: Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel. , 2019, , .		0
44	Abstract CT237: Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel. , 2019, , .		0
45	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 439-448.	13.9	3,680
46	Paediatric patients with acute leukaemia and <scp>KMT</scp>2A (<scp>MLL</scp>) rearrangement show a distinctive expression pattern of histone deacetylases. British Journal of Haematology, 2018, 182, 542-553.	1.2	7
47	Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia. Blood, 2018, 132, 895-895.	0.6	70
48	Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel. Blood, 2018, 132, 1551-1551.	0.6	12
49	Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients. Blood, 2018, 132, 899-899.	0.6	4
50	Considerations for tisagenlecleucel dosing rationale.. Journal of Clinical Oncology, 2018, 36, e15056-e15056.	0.8	7
51	Spuriously low pulse oximetry saturation associated with hemoglobin Sydney in a child and relatives: Identification of this unstable hemoglobin may avoid unnecessary testing and hospital admissions. Pediatric Blood and Cancer, 2017, 64, e26317.	0.8	1
52	Asparaginasas en el tratamiento de la leucemia linfoblÃ¡stica aguda. Medicina ClÃnica, 2017, 148, 225-231.	0.3	3
53	Intravenous pentamidine for Pneumocystis pneumonia prophylaxis in children undergoing autologous hematopoietic stem cell transplant. Pediatric Blood and Cancer, 2017, 64, e26558.	0.8	2
54	Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S263-S264.	0.2	41

#	Article	IF	Citations
55	Asparaginase use for the treatment of acute lymphoblastic leukemia. Medicina ClÃnica (English) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.1	3
56	Early clinical trials in paediatric oncology in Spain: A nationwide perspective. Anales De PediatrÃa (English Edition), 2017, 87, 155-163.	0.1	0
57	Influence of new antiretrovirals on hematological toxicity in HIV-exposed uninfected infants. European Journal of Pediatrics, 2016, 175, 1013-1017.	1.3	11
58	Aplastic Crisis Secondary to Parvovirus B19 Infection as the First Manifestation of an Undiagnosed Hereditary Spherocytosis. Journal of Pediatric Hematology/Oncology, 2016, 38, 81-82.	0.3	5
59	Landscape of early clinical trials for childhood and adolescence cancer in Spain. Clinical and Translational Oncology, 2016, 18, 708-713.	1.2	4
60	Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 2016, 128, 221-221.	0.6	62
61	FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget, 2016, 7, 49786-49799.	0.8	12
62	Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome. Usefulness of UGT1A1 mutational screening. Pediatric Blood and Cancer, 2015, 62, 1195-1201.	0.8	11
63	C0077: Heritable Trombophilia and Use of Primary Prophylaxis in Paediatric Patients with Acute Lymphoblastic Leukemia. Thrombosis Research, 2014, 133, S102.	0.8	0
64	Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases. Human Mutation, 2014, 35, 15-26.	1.1	101
65	Prophylaxis of Invasive Pulmonary Aspergillosis with Nebulized Lipid Complex Amphotericin B Is Feasible, Well Tolerated and Safe in Children with Acute Leukemia. Results of a Phase II Open Trial. Blood, 2014, 124, 1409-1409.	0.6	0
66	Successful port-a-cath salvage using linezolid in children with acute leukemia. Pediatric Blood and Cancer, 2013, 60, E103-E105.	0.8	3
67	Multiplex real-time PCR for prompt diagnosis of an outbreak of human parainfluenza 3 virus in children with acute leukemia. Infection, 2013, 41, 1171-1175.	2.3	8
68	Longer followâ€up confirms major improvement in outcome in children and adolescents with <scp>P</scp>hiladelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the <scp>S</scp>panish <scp>C</scp>ooperative <scp>S</scp>tudy <scp>SHOP</scp>/<scp>ALL</scp>â€2005. British Journal of Haematology, 2013, 162, 419-421.	1.2	9
69	Prospective Surveillance Study of Blood Stream Infections Associated With Central Venous Access Devices (Port-type) in Children With Acute Leukemia. Journal of Pediatric Hematology/Oncology, 2013, 35, e194-e199.	0.3	19
70	Abstract C46: Implication of FLT3 in human equilibrative nucleoside transporter 1 (hENT1)-mediated uptake of Ara-C in pediatric acute leukemia.. , 2013, , .		0
71	FLT3 Is Involved In Ara-C Transport By Human Equilibrative Nucleoside Transporter (hENT1) In Pediatric Acute Leukemia. Blood, 2013, 122, 3844-3844.	0.6	4
72	Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics Journal, 2012, 12, 379-385.	0.9	42

#	Article	IF	Citations
73	High resolution melting analysis for the identification of novel mutations in DKC1 and TERT genes in patients with dyskeratosis congenita. Blood Cells, Molecules, and Diseases, 2012, 49, 140-146.	0.6	21
74	Validation of the â€˜French Acute Lymphoblastic Leukaemia Study Group FRALLE prognostic indexâ€™ for paediatric Philadelphiaâ€chromosome acute lymphoblastic leukaemia. British Journal of Haematology, 2012, 156, 284-286.	1.2	3
75	Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosomeâ€positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALLâ€94, ALLâ€99 and ALLâ€2005. British Journal of Haematology, 2011, 154, 600-611.	1.2	50
76	Very high Hypertriglyceridemia Induced: Is Plasmapheresis Needed?. Pediatric Blood and Cancer, 2011, 57, 532-532.	0.8	6
77	Syndromic albinism and haemophagocytosis. British Journal of Haematology, 2010, 148, 815-815.	1.2	3
78	Pandemic influenza A (2009 H1N1) in children with acute lymphoblastic leukaemia. British Journal of Haematology, 2010, 149, 874-878.	1.2	41
79	Intermediate Dose of Imatinib In Combination with Chemotherapy Followed by Allogeneic Stem Cell Transplantation (SCT) Improves Early Outcome In Childhood Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Results of the Spanish Cooperative Group SHOP/SEHOP Studies SHOP 94, SHOP 99 and SHOP 05. Blood, 2010, 116, 3247-3247.	0.6	1
80	Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis. Haematologica, 2007, 92, 674-677.	1.7	28
81	Eosinophilic Ascites as the First Sign of Idiopathic Hypereosinophilic Syndrome in Childhood. Journal of Clinical Gastroenterology, 2007, 41, 864-865.	1.1	7
82	Idiopathic Hypereosinophilic Syndrome in Children. Journal of Pediatric Hematology/Oncology, 2005, 27, 663-665.	0.3	38
83	Nosocomial infections among pediatric hematology/oncology patients: Results of a prospective incidence study. American Journal of Infection Control, 2004, 32, 205-208.	1.1	45
84	â€˜Lymphoidâ€™ blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. British Journal of Haematology, 1998, 100, 129-134.	1.2	79